Author Relationships With Industry and Other Entities (Relevant)—2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease
| Writing Group Member |
Employment | Consultant | Speaker’s Bureau |
Ownership/ Partnership/ Principal |
Personal Research |
Institutional, Organizational, or Other Financial Benefit |
Expert Witness |
Voting Recusal (by Section)* |
|---|---|---|---|---|---|---|---|---|
| Thom W. Rooke, Chair | Mayo Clinic—Professor of Medicine | None | None | None | None | None | None | None |
| Alan T. Hirsch, Vice Chair | University of Minnesota Medical School: Cardiovascular Division—Vascular Medicine Program: Director; Professor of Medicine: Epidemiology and Community Health | •eV3 | None | None | None | None | 2.5.1 2.6.1.6 2.6.3 |
|
| Sanjay Misra, Vice Chair | Mayo Clinic: Division of Vascular and Interventional Radiology—Associate Professor of Radiology | •Johnson & Johnson | None | None | None | None | None | 2.6.3 |
| Anton N. Sidawy, Vice Chair | George Washington University—Professor and Chairman, Department of Surgery | None | None | None | None | None | None | None |
| Joshua A. Beckman | Brigham and Women’s Hospital Cardiovascular Division: Cardiovascular Fellowship Program—Director | None | None | None | None | None | 2.6.1.6 | |
| Laura K. Findeiss | University of California, Irvine: Chief, Division of Vascular and Interventional Radiology—Associate Professor of Radiology and Surgery | None | None | None | None | None | None | None |
| Jafar Golzarian | University of Minnesota Medical School—Professor of Radiology and Surgery | None | None | None | None | None | None | None |
| Heather L. Gornik | Cleveland Clinic Foundation Cardiovascular Medicine: Noninvasive Vascular Laboratory—Medical Director | None | None | None | •Summit Doppler Systems† | •Summit Doppler Systems† | None | 2.5.1 |
| Jonathan L. Halperin | Mount Sinai Medical Center—Professor of Medicine | None | None | •NIH-NHLBI (DSMB) | None | None | 2.6.1.6 | |
| Michael R. Jaff | Harvard Medical School—Associate Professor of Medicine | None | None | None | None | None | 2.6.3 | |
| Gregory L. Moneta | Oregon Health & Science University—Chief and Professor of Vascular Surgery | None | None | None | None | None | None | None |
| Jeffrey W. Olin | Mount Sinai School of Medicine—Professor of Medicine and Director of the Vascular Medicine Program | •Genzyme | None | None |
|
None | •Defendant; pulmonary embolism; 2009 | 2.6.1.6 |
| James C. Stanley | University of Michigan, Division of Vascular Surgery, University Hospital—Handleman Professor of Surgery | None | None | None | None | None | None | None |
| Christopher J. White | Ochsner Clinic Foundation: Department of Cardiology—Chairman | None | None | None | None | None | 2.6.3 5.2.6 |
|
| John V. White | Advocate Lutheran General Hospital—Chief of Surgery | None | None | None | None | None | None | None |
| R. Eugene Zierler | University of Washington—Professor of Surgery | None | None | None | None | None | None | None |
This table represents the relationships of writing group members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing group during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.
According to the ACCF/AHA, a person has a relevant relationship IF: (a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or (b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or (c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.
Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply.
Indicates significant relationship.
No financial benefit.
DSMB indicates Data and Safety Monitoring Board; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; and PI, principal investigator.